Načítá se...

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

BACKGROUND: This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively). PATIENTS AND METHODS: Patients received olaratumab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Oncol
Hlavní autoři: Wagner, A. J., Kindler, H., Gelderblom, H., Schöffski, P., Bauer, S., Hohenberger, P., Kopp, H.-G., Lopez-Martin, J. A., Peeters, M., Reichardt, P., Qin, A., Nippgen, J., Ilaria, R. L., Rutkowski, P.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5391707/
https://ncbi.nlm.nih.gov/pubmed/28426120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw659
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!